Several other research firms have also commented on CLVS. ValuEngine lowered shares of Clovis Oncology from a hold rating to a sell rating in a report on Friday, May 19th. BidaskClub upgraded shares of Clovis Oncology from a hold rating to a buy rating in a report on Wednesday, June 21st. Cann reiterated a hold rating on shares of Clovis Oncology in a research note on Monday, September 11th. Evercore ISI initiated coverage on shares of Clovis Oncology in a research note on Wednesday, August 16th. They set an in-line rating and a $73.00 price objective on the stock. Finally, SunTrust Banks, Inc. reiterated a buy rating on shares of Clovis Oncology in a research note on Thursday, June 22nd. Nine equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Clovis Oncology currently has a consensus rating of Buy and a consensus price target of $84.91.
Clovis Oncology (NASDAQ CLVS) opened at 76.95 on Monday. Clovis Oncology has a one year low of $25.50 and a one year high of $99.45. The company’s market cap is $3.76 billion. The company has a 50-day moving average of $73.35 and a 200 day moving average of $69.15.
Clovis Oncology (NASDAQ:CLVS) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.27) by ($0.02). The company had revenue of $14.62 million for the quarter, compared to analyst estimates of $13.07 million. During the same quarter in the previous year, the company earned ($2.07) earnings per share. The business’s revenue was down 32.5% on a year-over-year basis. Analysts anticipate that Clovis Oncology will post ($7.56) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Clovis Oncology, Inc. (NASDAQ:CLVS) Rating Reiterated by Oppenheimer Holdings, Inc.” was published by BBNS and is the property of of BBNS. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://baseballnewssource.com/markets/oppenheimer-holdings-inc-reiterates-hold-rating-for-clovis-oncology-inc-clvs/1634295.html.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $91.56, for a total value of $274,680.00. Following the sale, the insider now directly owns 197,583 shares in the company, valued at $18,090,699.48. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director James C. Blair sold 18,450 shares of the business’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the completion of the sale, the director now owns 2,185 shares in the company, valued at $171,762.85. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 27,450 shares of company stock worth $2,143,685. Company insiders own 17.40% of the company’s stock.
A number of institutional investors have recently modified their holdings of CLVS. Phocas Financial Corp. bought a new stake in Clovis Oncology in the second quarter worth about $112,000. First Mercantile Trust Co. acquired a new stake in Clovis Oncology during the 1st quarter worth about $115,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Clovis Oncology by 71.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 758 shares during the period. Advisors Asset Management Inc. raised its holdings in Clovis Oncology by 160.7% during the 2nd quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 1,168 shares during the period. Finally, PNC Financial Services Group Inc. raised its holdings in Clovis Oncology by 3.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 100 shares during the period. Hedge funds and other institutional investors own 99.03% of the company’s stock.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with our FREE daily email newsletter.